- Home
- HRTX vs SGMO Comparison
HRTX vs SGMO Comparison
Compare HRTX & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRTX | SGMO |
|---|---|---|
| Founded | 1983 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 141.2M |
| IPO Year | 2007 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HRTX | SGMO |
|---|---|---|
| Price | $1.05 | $0.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.50 | ★ $7.00 |
| AVG Volume (30 Days) | 1.8M | ★ 6.6M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.20 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | $36,567,000.00 |
| Revenue This Year | $15.28 | $24.46 |
| Revenue Next Year | $20.29 | $193.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.36 | ★ 88.60 |
| 52 Week Low | $0.74 | $0.21 |
| 52 Week High | $2.61 | $0.84 |
Technical Indicators
Market Signals| Indicator | HRTX | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 42.07 |
| Support Level | $1.03 | $0.21 |
| Resistance Level | $1.31 | $0.55 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 98.41 | 65.19 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.